Cargando…

Antidiabetic activity of Chandraprabha vati – A classical Ayurvedic formulation

BACKGROUND: Chandraprabha vati is a classical Ayurvedic formulation, markedly used for mitigation of Prameha, which correlates in many ways with obesity, metabolic syndrome and diabetes mellitus. OBJECTIVE: The present study was aimed to investigate effect of Chandraprabha vati in experimentally-ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanjari, Manish M., Mishra, Sujata, Dey, Yadu Nandan, Sharma, Deepti, Gaidhani, Sudesh N., Jadhav, Ankush D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052381/
https://www.ncbi.nlm.nih.gov/pubmed/27665674
http://dx.doi.org/10.1016/j.jaim.2016.08.010
_version_ 1782458222964113408
author Wanjari, Manish M.
Mishra, Sujata
Dey, Yadu Nandan
Sharma, Deepti
Gaidhani, Sudesh N.
Jadhav, Ankush D.
author_facet Wanjari, Manish M.
Mishra, Sujata
Dey, Yadu Nandan
Sharma, Deepti
Gaidhani, Sudesh N.
Jadhav, Ankush D.
author_sort Wanjari, Manish M.
collection PubMed
description BACKGROUND: Chandraprabha vati is a classical Ayurvedic formulation, markedly used for mitigation of Prameha, which correlates in many ways with obesity, metabolic syndrome and diabetes mellitus. OBJECTIVE: The present study was aimed to investigate effect of Chandraprabha vati in experimentally-induced hyperglycemia and lipid profile alterations. MATERIALS AND METHODS: Antidiabetic effect of Chandraprabha vati was studied in fifty five Wistar rats. Graded doses of Chandraprabha vati (50, 100 and 200 mg/kg) were administered orally for 7 days to normal and alloxan-hyperglycemic rats (65 mg/kg, intravenously), and to glucose loaded normal rats for oral glucose tolerance test (OGTT). Fasting plasma glucose levels were assessed on different time intervals along with plasma cholesterol and triglycerides. Metformin (500 mg/kg, orally) was used as standard drug. RESULTS: Chandraprabha vati did not cause any significant reduction in plasma glucose levels of normal rats (p > 0.05) but normalized the impaired glucose tolerance at 60 and 120 min (p < 0.05–p < 0.001) in OGTT when compared to vehicle control. In alloxan-hyperglycemic rats, administration of Chandraprabha vati (200 mg/kg) significantly reduced plasma glucose at 3 h, 12 h, 3rd day and 7th day (p < 0.01–p < 0.001) along with reduction in cholesterol and triglycerides levels (p < 0.01–p < 0.001) when compared to diabetic control group. The effects were comparable with metformin. CONCLUSIONS: Chandraprabha vati exhibited anti-hyperglycemic effect and attenuated alterations in lipid profile. The results support the use of Chandraprabha vati for correction of Prameha in clinical practice.
format Online
Article
Text
id pubmed-5052381
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-50523812016-10-12 Antidiabetic activity of Chandraprabha vati – A classical Ayurvedic formulation Wanjari, Manish M. Mishra, Sujata Dey, Yadu Nandan Sharma, Deepti Gaidhani, Sudesh N. Jadhav, Ankush D. J Ayurveda Integr Med Original Research Article (Experimental) BACKGROUND: Chandraprabha vati is a classical Ayurvedic formulation, markedly used for mitigation of Prameha, which correlates in many ways with obesity, metabolic syndrome and diabetes mellitus. OBJECTIVE: The present study was aimed to investigate effect of Chandraprabha vati in experimentally-induced hyperglycemia and lipid profile alterations. MATERIALS AND METHODS: Antidiabetic effect of Chandraprabha vati was studied in fifty five Wistar rats. Graded doses of Chandraprabha vati (50, 100 and 200 mg/kg) were administered orally for 7 days to normal and alloxan-hyperglycemic rats (65 mg/kg, intravenously), and to glucose loaded normal rats for oral glucose tolerance test (OGTT). Fasting plasma glucose levels were assessed on different time intervals along with plasma cholesterol and triglycerides. Metformin (500 mg/kg, orally) was used as standard drug. RESULTS: Chandraprabha vati did not cause any significant reduction in plasma glucose levels of normal rats (p > 0.05) but normalized the impaired glucose tolerance at 60 and 120 min (p < 0.05–p < 0.001) in OGTT when compared to vehicle control. In alloxan-hyperglycemic rats, administration of Chandraprabha vati (200 mg/kg) significantly reduced plasma glucose at 3 h, 12 h, 3rd day and 7th day (p < 0.01–p < 0.001) along with reduction in cholesterol and triglycerides levels (p < 0.01–p < 0.001) when compared to diabetic control group. The effects were comparable with metformin. CONCLUSIONS: Chandraprabha vati exhibited anti-hyperglycemic effect and attenuated alterations in lipid profile. The results support the use of Chandraprabha vati for correction of Prameha in clinical practice. Elsevier 2016 2016-09-22 /pmc/articles/PMC5052381/ /pubmed/27665674 http://dx.doi.org/10.1016/j.jaim.2016.08.010 Text en © 2016 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article (Experimental)
Wanjari, Manish M.
Mishra, Sujata
Dey, Yadu Nandan
Sharma, Deepti
Gaidhani, Sudesh N.
Jadhav, Ankush D.
Antidiabetic activity of Chandraprabha vati – A classical Ayurvedic formulation
title Antidiabetic activity of Chandraprabha vati – A classical Ayurvedic formulation
title_full Antidiabetic activity of Chandraprabha vati – A classical Ayurvedic formulation
title_fullStr Antidiabetic activity of Chandraprabha vati – A classical Ayurvedic formulation
title_full_unstemmed Antidiabetic activity of Chandraprabha vati – A classical Ayurvedic formulation
title_short Antidiabetic activity of Chandraprabha vati – A classical Ayurvedic formulation
title_sort antidiabetic activity of chandraprabha vati – a classical ayurvedic formulation
topic Original Research Article (Experimental)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052381/
https://www.ncbi.nlm.nih.gov/pubmed/27665674
http://dx.doi.org/10.1016/j.jaim.2016.08.010
work_keys_str_mv AT wanjarimanishm antidiabeticactivityofchandraprabhavatiaclassicalayurvedicformulation
AT mishrasujata antidiabeticactivityofchandraprabhavatiaclassicalayurvedicformulation
AT deyyadunandan antidiabeticactivityofchandraprabhavatiaclassicalayurvedicformulation
AT sharmadeepti antidiabeticactivityofchandraprabhavatiaclassicalayurvedicformulation
AT gaidhanisudeshn antidiabeticactivityofchandraprabhavatiaclassicalayurvedicformulation
AT jadhavankushd antidiabeticactivityofchandraprabhavatiaclassicalayurvedicformulation